Lymphoma Survivor chosen as Seattle Cancer Care Alliance advocate

Last year, I posted about Pamela Clark who is a pro surfer and Hodgkin's Lymphoma survivor. The Seattle Cancer Care Alliance (SCCA) has chosen Pamela as their cancer advocate. She appears in a full page ad for SCCA in three magazines - Sunset (Nov), Seattle (Sept), Horizon Air (Oct), and Alaska Air (Oct).



The ad starts out with:



Serious surfer

Substance abuse scientist

Dedicated do-gooder

Loving Wife

Hodgkin's Disease survivor



In her line to me, she says the picture, by Kevin Cruff, far from being taken on a sunny day, was actually taken on a very cold day at Ecola State Park (near Cannon Beach, Oregon). The camera is far enough away to hide the goosebumps!



Having gone to Fred Hutchinson in Seattle myself for second opinion with a renouned oncologist, I know they're good.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap